Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Table 4 Stratified analyses of the interaction between PLR and BMI in relation to overall survival in patients with g-NEN

	Crude model		P_interaction	Model I		P_interaction	Model II		P_interaction
	HR (95% CI)	P value	P_interaction	HR (95% CI)	P value	P_interaction	HR (95% CI)	P value	P_interaction
PLR (per SD)			0.006			0.008			0.007
BMI < 25	2.02 (1.46, 2.78)	< 0.001		1.96 (1.42, 2.72)	< 0.001		1.95 (1.38, 2.76)	< 0.001
BMI >= 25	1.13 (0.86, 1.49)	0.390		1.12 (0.84, 1.48)	0.448		1.04 (0.75, 1.44)	0.815
PLR (Q4 vs Q1–3)			0.179			0.159			0.047
BMI < 25	2.45 (1.33, 4.48)	0.004		2.38 (1.29, 4.39)	0.005		2.22 (1.14, 4.30)	0.019
BMI >= 25	1.25 (0.58, 2.66)	0.569		1.17 (0.55, 2.51)	0.682		1.44 (0.64, 3.26)	0.378

Abbreviations: SD standard deviation, CI indicates confidence interval, HR hazard ratio, PLR platelet to lymphocyte ratio, IQR interquartile range, BMI body mass index. The values in this table are expressed as the format of HR (95% CI) P value
Crude model did not adjust covariant
Model I minimally adjusted for sex and age
Model II fully adjusted for sex, age, tumor size, and N stage

ISSN: 1477-7819